Fåhraeus Startup and Growth Fund was started in 2021 by Christer Fåhraeus and Emanuel Eriksson. It is a Venture Capital fund focusing on investing early in companies in life science and tech. The goal of the investments is to take the companies up for sale or listing on the stock exchange a few years after the investment. Christer and Emanuel, together with Linus Wiebe, manage the fund.
History of the fund
In recent years, Christer Fåhraeus and Emanuel Eriksson have worked together with investments in small listed companies and unlisted life science and tech companies for Fårö Capital. Fårö Capital is a Family Office fund where Christer has been CEO and Emanuel Investment Manager. During the years at Fårö Capital, they decided to raise a fund for investments in companies in the same industry with excellent growth potential.
Sustainability
Fåhraeus Startup & Growth has integrated sustainability risks into the investment decision process at all stages of the investment life cycle. Sustainability risks include environmental, social or governance-related events or circumstances that may have a significant adverse effect on the value of the investment. The risks are initially assessed together with other types of risks as part of the due diligence work before the investment takes place. The various factors are prioritized depending on how important they are for the business, the stakeholders and the expected effect on the investment. A conclusion that there are significant sustainability risks that will not be manageable or limited results in a decision not to invest.
Fåhraeus Startup & Growth does not consider the main negative consequences of investment decisions for sustainability factors because, given the fund’s size and investment strategy, it is not possible to carry out reliable due diligence from a cost-benefit perspective. However, the fund continues to evaluate and consider its obligations regarding the investments’ main negative consequences for sustainability factors. Decisions and publications can be reviewed once the technical standards have been adopted and when data and tools for measuring the significant negative consequences regarding unlisted life science and technology companies have been developed and become more efficient. Before making an investment decision, the long-term effects of the investment are taken into account, and the fund avoids taking short-term risks to achieve a profit.